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This review provides an overview of Marfan syndrome with an emphasis on cardiovascular complications and
cardiovascular imaging. Both pre- and post-operative imaging is addressed with an explanation of surgical
management. All relevant imaging modalities are discussed with a particular focus on cardiovascular MR.
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Marfan syndrome (MFS) is a disorder of connective tis-
sue structure and function, with a reported incidence of
approximately 1 in 5000 individuals [1]. With no predilec-
tion for gender or ethnicity the UK prevalence is in the re-
gion of 10,000. In 1896, Professor Antoine Bernard-Jean
Marfan, founder of paediatrics in France, described a 5 year
old girl with disproportionately long limbs and digits and
called the condition, dolichostenomelie (slender limbs).
His subsequent work led to the eponymous naming of
Marfan syndrome, (although this ‘index case’ is now felt to
represent congenital contractural arachnodactyly, a pheno-
typically similar but separate condition) [1]. However, it
was not until the 1930’s that the associated cardiovascular
complications began to be recognised in the Western
medical literature.
Other pathologies overlap clinically with Marfan syn-
drome. In ectopia lentis syndrome, lens dislocation occurs
without the associated cardiac abnormalities; with familial
thoracic aortic syndrome, aortic pathology exists without
other features of MFS and Loeys-Dietz syndrome.
With our understanding of phenotypic variance, inter-
nationally agreed clinical criteria were defined, initially
in 1986 (Berlin nosology) [2] and later revised in the Ghent
nosology of 1996 [3]. A further revision of the guidelines
proposed aortic root aneurysm and lens dislocation as car-
dinal clinical features [4], see Table 1 and 2 (A web based* Correspondence: r.mohiaddin@imperial.ac.uk
2Royal Brompton Hospital and National Heart & Lung Institute, Imperial
College, Sydney Street, London SW3 6NP, UK
Full list of author information is available at the end of the article
© 2013 Dormand and Mohiaddin; licensee Bio
the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumdiagnostic tool for application of these criteria is available
at www.marfan.org).Genetic basis and pathogenesis
MFS is an autosomal dominant condition exhibiting
complete penetrance but variable expression. Up to one
third of cases are thought to be spontaneous mutations,
higher than previously thought [5,6]. Rarer recessive
conditions displaying the MFS phenotype have also been
described [7]. In the majority of cases a mutation in the
fibrillin 1 (FBN1) gene located on chromosome 15 causes
the fibrillinopathy [8]. The fibrillin glycoprotein was dis-
covered in 1986 and linked in 1991 to the FBN1 gene,
chromosome 15 and MFS [9]. FBN1 molecular analysis,
now in clinical practice, provides valuable diagnostic infor-
mation, particularly in children in whom aortic dilatation
may not initially be present [10].
Histological abnormalities in the aortic wall were
recognised by the 1950’s and descriptions can be found of
disrupted elastic lamella; disorganised and hypertrophied
smooth muscle fibres with increased vascular channels
from the media to adventitia [11]. Over time, refined histo-
logical study revealed degradation of the extracellular
matrix referred to previously as ‘cystic medial necrosis’ [12].
Fibrillin1 is a major component of 10-12 nm microfibrils
which are an integral part of elastic connective tissues.
They have complex structural, expansile and anchoring
roles which are yet to be fully elucidated [9]. However,
MFS is not merely a consequence of inherently weakened
connective tissue as originally thought. Instead evidence
from murine models now points towards an additional fail-
ure of appropriate maintenance of elastic fibres (Figures 1Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Simplified revised Ghent criteria








Aorta (Z≥ 2 or dissection)
and ectopia lentis
Yes Ectopia lentis Yes
Aorta (Z≥ 2 or dissection)
and a causal FBN1 mutation
Yes Systemic score≥ 7 Yes
Aorta (Z≥ 2 or dissection)
and systemic features (≥7)
Yes Aorta (Z≥ 2 above
20 yr old, Z≥ 3
below 20 yr, or
dissection)
Yes




Z-score is derived from a measurement of the sinus of Valsalva indexed to
body surface area.
Caveat: other conditions such as Loeys-Dietz syndrome must be excluded. Figure 1 Haematoxylin and eosin stain showing cystic change
in the vascular media in MFS.
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ing protein dysregulation by microfibrils is an important
mechanism in MFS pathogenesis and can explain the
phenotypic features found in many connective tissues
[13,14]. The proteases involved in extracellular matrix deg-
radation have also come under scrutiny and recent work
has focused on matrix metalloproteinases and serine pro-
teinases. These are implicated in all thoracic aneurysmal
syndromes, not just MFS. In the aorta the defective tissues
have increased alcianophilic glycosominoglycans, vacuoles
secondary to the loss of smooth muscle cells and disor-
dered adhesive protein. This renders them more suscep-
tible to shear stress leading, over time, to dilatation and
dissection.Table 2 Scoring of systemic features
Feature Score
Wrist and thumb sign 3








Reduced upper/lower segment ratio and increased
arm span/height and no severe scoliosis
1
Scoliosis or thoracolumbar kyphosis 1
Reduced elbow extension 1
Facial features (3/5) 1
Skin striae 1
Myopia > 3 diopters 1
Mitral valve prolapsed 1
Maximum total 20.Systemic manifestations of MFS
The systems classically thought to be affected by MFS
are cardiovascular, ocular and skeletal (see Table 1). Car-
diovascular manifestations, particularly aortic dissection
are the most common cause of death. Cardiovascular
imaging is therefore fundamental to the screening, diag-
nosis and lifelong monitoring of these individuals.
Upward subluxation of the lens (ectopia lentis) may
be present in up to 80% patients; there is a tendency
to myopia and an increased risk of retinal detachment
[5]. Annual ophthalmological evaluation is advised. Al-
though skeletal features may be most noted by clinicians,
they feature less prominently in revised diagnostic guide-
lines and include dolichostenomelia (increased length of
the limbs as compared with the trunk), arachnodactyly,
scoliosis, pectus excavatum (Figure 3) or carinatum and
dural ectasia (Figure 4). Pneumothorax and skin striae
are also recognised systemic features.Figure 2 Trichrome stain where elastic fibres are black showing
their destruction and fragmentation.
Figure 3 Pectus Excavatum in panel on the left with corresponding CMR image on the right.
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The diagnosis of MFS is complicated by its overlapping
phenotype with other conditions and is best made by an
expert in this area, following internationally agreed criteria.
For example, Professor Marfan’s index case is now thought
to have had congenital contractural arachnodactyly which
is related to mutations in the gene encoding for fibrillin 2
[12]. It is still fairly recently that Loeys-Dietz syndrome
was recognised and is characterised by arterial tortuousity
and aneurysms, hypertelorism, and bifid uvula or cleft pal-
ate. It is caused by heterozygous mutations in the genesFigure 4 CMR demonstrating dural ectasia. This is ballooning or wideni
It may be associated with herniation of the nerve root sleeves through theencoding for transforming growth factor β receptors 1 and
2 (TGFBR1, TGFBR2). Individuals with this autosomal
dominant condition have aortic aneurysm formation and
dissection at a much younger age than those with MFS
and require annual MR of the vasculature from cerebrum
to pelvis [15].
When mutations in fibrillin genes or TGFBR1 or 2 are
present without full phenotypic features of MFS or
Loeys-Dietz, then individuals may be classified into any
number of groups including ecoptia lentis syndrome
and MASS syndrome (mitral, aortic, skeletal, skin), withng of the dural sac and has been the subject of various classifications.
ir associated foramina [134]. See arrows.





Left ventricular impairment 25%
Mitral/Aortic Valves 80%/50%
Pulmonary Artery Dilatation 10%
For references see relevant section below.
Dormand and Mohiaddin Journal of Cardiovascular Magnetic Resonance 2013, 15:33 Page 4 of 28
http://www.jcmr-online.com/content/15/1/33some requiring imaging, particularly children in whom
vascular features may present later and the diagnosis be
changed. Type IV Ehlers-Danlos syndrome also predis-
poses to aortic dissection.
Significant numbers of thoracic aortic aneurysms are
thought to follow an inherited pattern, even when no
named syndromic cause can be identified, and screening
for aortic and cerebral aneurysms in first degree relatives
of affected individuals has been advocated [16].
Treatment and prognosis in MFS
Medical therapy to reduce the rate of aortic dilatation
and risk of dissection, once MFS has been diagnosed, is
now advocated. Although experiments in turkeys over
50 years ago demonstrated that propranolol was effective
in reducing death from dissecting aortic aneurysms [17],
initial work in humans was not as successful [18]. There-
fore it was not until 1994 that beta - blockade with pro-
pranolol was shown to be effective in slowing the rate of
aortic dilatation and reducing the rate of complications
in some people with MFS [19]. The beta-blocker should
be titrated to effect, aimed at a heart rate after submaximal
exercise of <100 beats/min in those over 5 years of age.
Resting heart rate should be <60 beats/min if blood pres-
sure will allow [6]. The rationale behind this therapy is one
of reducing aortic wall shear stress by reducing the rate of
pressure change in the aortic root and heart rate [20]. Sub-
sequent work in a murine model of MFS demonstrated
that losartan was effective in reducing aortic pathological
changes and dilatation. Retrospective analysis in a group of
paediatric patients with MFS appears to support this find-
ing [21]. There is also evidence demonstrating that the
ACE inhibitor perindopril reduces both aortic stiffness and
aortic root diameter in MFS when taken in addition to
beta-blockers [22]. Several randomised controlled trials are
currently underway to evaluate the role of angiotensin re-
ceptor blockers and beta-blockers in MFS and should add
considerably to our knowledge base.
If aortic dissection does occur then it constitutes a med-
ical emergency. The majority of cases are Type A dissec-
tions usually necessitating surgery. Surgical treatment for
aortic complications of Marfan syndrome continues to
progress and will be discussed separately in the review.
Lifelong imaging is recommended after aortic root surgery.
Exercise restriction may be recommended on an individ-
ual basis a part of the management of MFS and guidelines
are provided by both the National Marfan Foundation
(www.marfan.org) and the American Heart Association/
American College of Cardiology task forces [23].
Earlier reports quoted a mean age at death of 32 years
[24] and more recently 40 years [25]. This significant in-
crease in life expectancy has been driven by medical and
surgical intervention and the median cumulative prob-
ability of survival,(age at which half of a cohort wouldstill be alive), has risen to around 70 years [26]. It has
been recognised for some time that a family history of
severe cardiovascular disease in MFS is associated with
increased aortic diameter and decreased survival in indi-
vidual patients [27].
Cardiovascular complications
The significance of morphological cardiovascular mani-
festations in MFS was recognised early on [28]. They
may be categorised as affecting the aorta, myocardium,
valves or pulmonary arteries (see Table 3 for frequency).
More recently the impact of skeletal abnormalities on
cardiac function has been appreciated [29,30]. All need
to be investigated by imaging.
Aorta
In MFS, the aorta becomes the critical ground for the
interplay between structural microfibril matrix abnormal-
ities, heightened by failure of standard maintenance pro-
grammes by TGFβ, and beat to beat haemodynamic
stressors. Endothelial shear stress, wall strain, torsion and
intrinsic wall stress make this a dangerous environment
for abnormal connective tissue. The result is a thinned
aortic wall which progressively dilates and loses distensi-
bility thereby heightening the risks of aneurysm formation
and dissection throughout its length, but particularly at
the root [6].
Cohort studies have shown that nearly 60% of those
with MFS have root dilatation at a mean age of 35 years,
with lower rates of more distal dilatation [31]. A review
of patients with an FBN1 mutation, 73% of whom had
MFS, demonstrated that the risk of ascending aortic
(AA) dilatation increases with age, reaching 96% by the
age of 60 years. Men were at higher risk than women for
AA dilatation, dissection or surgery [32].
Dissection is said to have occurred when the media is
separated from the other aortic layers due to bleeding
within and along the wall of the aorta. This is usually
secondary to an intimal tear. It can be classified ana-
tomically according to whether the ascending aorta is
involved or by the site of the intimal tear, (Figure 5). This
classification is important in clinical decision-making.
Dissection is acute if less than 2 weeks between onset
of symptoms and presentation; subacute if 2 to 6 weeks
gap; and chronic if more than 6 weeks has elapsed [33].
Figure 5 Stanford and De Bakey classification of aortic dissection. The image on the left represents De Bakey I and II/Stanford A; the middle
image Stanford B; the right image De Bakey IIIa and b/Stanford B. De Bakey I; -origin in ascending aorta; extends to include at least arch; -usually surgical
management. De Bakey II; -originates in and is confined to ascending aorta; -usually surgical management. De Bakey IIIa; -originates in descending aorta;
usually extends distally; -usually nonsurgical management De Bakey IIIb; -originates in descending aorta; extends distally below diaphragm; -usually
nonsurgical management. Stanford A; -all dissections involving ascending aorta; -management usually surgical. Stanford B; -all dissections not involving
ascending aorta; -management usually nonsurgical.
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acute, subacute or chronic.
Acute aortic dissection usually presents with pain, al-
though around 6% of all dissections are painless but as-
sociated with increased mortality [34]. Approximately
one quarter of those with untreated proximal dissections
die within 24 hr of initial presentation. Death is usually
from acute severe aortic regurgitation, aortic rupture or
major branch vessel compromise.
Of those experiencing pain, it is usually midline and
may be in the chest, back or abdomen depending on the
location of the dissection. Onset is usually abrupt but
only around half of patients describe the classical ‘tear-
ing’ or ‘ripping’ quality so often highlighted at medical
school. If this pain abates but then recurs it may indicate
dissection extension and impending aortic rupture [35].
As extension occurs it may directly involve the walls
of branch arteries. Alternatively branches may be com-
pressed by expansion of a false lumen. Either mechanism
leads to end organ compromise and additional systemic
manifestations.
If the root is involved then aortic regurgitation may
occur, as may pericardial effusion. Cardiac ischaemia may
be the result of coronary artery involvement. However, re-
gional wall motion abnormalities may occur as a result of
generally low coronary perfusion pressures. Involvementof head and neck vessels can manifest as stroke or periph-
eral ischaemia. Peripheral ischaemia will lead to localising
pain, pallor, paraesthesias and pulselessness of upper or
lower limbs. Pulse deficit occurs in around 30% of patients
and is associated with a poorer prognosis [36].
When renal ischaemia is present, there may be pain,
haematuria, fever and biochemical abnormalities. The left
renal artery is compromised more often than the right. If
mesenteric ischaemia is present then there may be pain
out of proportion to clinical findings and profound lactic
acidosis. This is associated with a high mortality [37].
If aortic dissection is suspected on the basis of clinical
assessment, then diagnostic imaging should be performed.
Choice of imaging technique depends on patient stability,
local expertise and availability. A second imaging modality
should be performed if the first imaging is negative but
clinical suspicion remains high.
Once dissection is confirmed then initial management is
aimed at limitation of propagation of the false lumen be-
fore a definitive management plan is instituted, (Figure 6).
In patients with MFS who have undergone aortic
aneurysm repair, the ascending aorta is usually the site
of the first operation, with mean age at time of surgery
of 32.4 years. The majority have subsequent dissections
or aneurysms, 95% of which are in other regions of the
aorta. The presence of dissection at the time of first
Figure 6 Management pathway for acute aortic dissection. Adapted from 2010 ACCF/AHA guidelines.
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surgery [38]. In aortic dissection survivors with MFS,
80% have involvement of the ascending aorta, but about
two thirds have involvement of the descending aorta or
pure descending aortic dissection. Of those with dissection
confined to the descending aorta, more than half have aor-
tic root diameters less than 5 cm. Just over half of all pa-
tients incur a further clinical event during follow-up,
usually in the descending aorta [39]. Of relevance, it has
been shown that patients who have undergone elective aor-
tic root surgery have a greater distal aortic diameter [40].
Aneurysms of the pulmonary trunk in MFS are rare
[41], although dilatation of the main pulmonary artery is
relatively common, occurring in over 10% patients [31,42].
Valves
Aortic, mitral and tricuspid valves can be involved in MFS.
The incidence of mitral valve prolapse and mitral regurgi-
tation increases steadily with age, (although severe forms
of MFS which may present in the neonatal period are asso-
ciated with severe mitral and tricuspid disease) [43]. A sur-
vey of young patients with MFS (mean age 11.9 years)
found over two thirds to have echocardiographic features
of mitral valve dysfunction, usually prolapse. More than
25% of the cohort had disease progression over the follow-
ing 4–6 years. However surgery for mitral regurgitation
alone is uncommon in adults. The severity of mitral regur-
gitation in adults is unrelated to gender, unlike the risk of
aortic dilatation and its complications [32].The mitral valve changes associated with MFS are dif-
ferent to those associated with classic myxomatous mi-
tral disease and are present in up to 80% adult patients.
In MFS the leaflets are longer and thinner with an in-
creased prevalence of bileaflet and anterior leaflet pro-
lapse. However, posterior leaflet prolapse remains the
most common valvular abnormality. In a surgical study
patients with MFS were less likely to receive mitral valve
repair than replacement. However, out of those receiving
repair, the results were excellent with 96% freedom from
reoperation at 10 years [44].
When the tricuspid valve is affected in MFS, it is usu-
ally in combination with the mitral valve. Similar to the
mitral valve the pathologic mechanism of regurgitation
is prolapse and the valve may be suitable for repair [45].
Aortic valve dysfunction is felt to be a later occurrence,
usually secondary to annular dilatation [31]. However, the
aortic valve is more than just a passive structure sitting
between the left ventricular outflow tract and the aortic
root. This is an important functional unit subject to com-
plex haemodynamic forces. The sinuses of Valsalva have a
particularly important role in the valve’s normal function.
As the aortic valve opens, the sinuses provide adequate
space to prevent occlusion of the coronary artery ori-
fices. In addition, this space permits the formation of
eddy currents which hold the leaflets away from the aor-
tic wall and facilitate appropriate valve closure at the
end of systole. In diastole the sinuses move outwards
and decrease the forces exerted on the valve leaflets.
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be moved outwards, thereby reducing leaflet coaptation
in diastole, but also impairing the ability of the aortic si-
nuses and valve to function as one unit, thereby acceler-
ating valvular dysfunction [46].
Myocardial involvement
Fujiseki and colleagues reported the first case of MFS-
associated myocardial involvement in 1984 [47]. Since
then both right and left ventricular dysfunction and a di-
lated cardiomyopathy phenotype have been described
[48]. Early studies using echocardiography found that a
small proportion of patients had altered left ventricular
dimensions [49]. Studies utilising more sensitive imaging
techniques in those without valvular disease identified
mild but significant impairment of left ventricular func-
tion [50]. Both systolic and diastolic impairment of func-
tion was identified by tissue doppler imaging (TDI).
Importantly echocardiography was unable to identify any
differences in left ventricular diameters, but CMR demon-
strated a significant increase in end-systolic volume cor-
rected for body surface area (BSA) and a decrease in
ejection fraction. Left ventricular dilatation may predis-
pose to alterations of repolarisation and fatal ventricular
arrhythmias [51].
Biventricular involvement in MFS is well recognised.
An echocardiographic study focusing on right ventricu-
lar systolic function found a reduction in the variables of
TAPSE; rate of pressure rise (dp/dt) and peak TDI ve-
locity of the basal lateral wall in those with MFS [52].
A comprehensive cardiac assessment was undertaken
by Alpendurada et al. using cardiovascular magnetic res-
onance [53]. Evaluating patients with MFS and without
cardiovascular surgery or significant valvular disease,
25% had a reduced left ventricular EF%. Just over 10%
patients also had reduced right ventricular EF%. No pa-
tient with a normal LVEF% had a reduced RVEF%.
Although the degree of ventricular impairment in the
vast majority of the patients featured in these imaging
studies was mild, it is still early in the recognition of a
‘MFS-associated cardiomyopathy’. The natural history ofTable 4 Surgical repair of aortic root/ascending aorta recomm
American guidelines
External diameter > 5.0 cm
Or at < 5.0 cm if: Growth at greater 0.5 cm/yr
Or Family history dissection at <5.0 c
Or Presence of significant aortic regu
Or in women contemplating pregnancy >4.0 cm
Also consider if: Maximum CSA/height in metres >
CSA = cross sectional area in cm2 of ascending aorta or root BSA = body surface are
* Shorter patients have dissection at a smaller size. 15% patients with MFS have dis
#Consider at 4.0-4.5 cm depending on serial growth on imaging and family historythis entity will be almost impossible to separate from devel-
oping aortic and valvular pathology in this patient group,
but most authors recognise opportunities for pharmaco-
logic intervention in these patients.
In addition to cardiomyopathic changes, the impact of
skeletal abnormalities in MFS should also be considered.
Recent studies have demonstrated that pectus excavatum
can reduce resting right ventricular function [30]. Surgi-
cal correction of this deformity may improve cardiac
function [29].
Criteria for aortic surgical intervention
Just over a decade ago published surgical cohorts had a
mean diameter of 6.8 cm, which was a reflection of both
varied surgical practice but also of late or missed diagnosis
of MFS in this patient population [54]. However the in-
creasing incidence of a poor outcome after emergency sur-
gery versus the low mortality of less than 2% for elective
aortic replacement was already recognised and increasing
numbers of surgeons were performing prophylactic root
replacement at a diameter of 5.5 - 6.0 cm. Some groups in
the late 1990’s were proposing a further reduction of this
value to 5.0 - 5.5 cm [54-56].
American and European guidelines published in 2010
advocate surgical repair of a dilated aortic root/ascending
aorta when the external diameter is 5.0 cm [33,57]. A sum-
mary and comparison of the guidelines is made in Table 4.
The American guidelines recognise the ongoing risk to
the arch and descending aorta as sites for the later de-
velopment of aneurysm formation and dissection, fol-
lowing prophylactic root repair. Routine lifelong imaging
of the entire aorta is recommended. Whilst less data is
available examining arch and descending aorta interven-
tion, recommendations are made that in the presence of
a chronic dissection, open repair of the descending tho-
racic aorta is undertaken at >5.5 cm. This is similar for
the thoraco-abdominal aorta. Arch aneurysms are usu-
ally associated with disease of the adjacent proximal or
distal aorta, and it is suggested that operative interven-
tion in these individuals should be guided by the same
parameters as for the adjacent segments.ended
European guidelines
External diameter > 5.0 cm
Or at 4.6-5.0 cm if: Dilatation at greater 0.2 cm/yr
m Or Family history dissection
rgitation Or Severe aortic or mitral regurgitation
Or Pregnancy is being planned#
10 * In ‘small’ individuals use: Indexed diameter adjusted for BSA
of 2.75 cm/m2 [58]
a.
section at aortic root diameters less than 5.0 cm.
[59].
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dissection elsewhere and patients should be considered
for surgery when other parts of the aorta are greater than
5.0 cm or progressive dilatation is evident [57].Surgical intervention
Surgery repairs or removes diseased tissue and struc-
tures, but alters the residual anatomy. Options for repair
cover the spectrum from valve sparing root replace-
ments to complete aortic valve, root and arch replace-
ments, as well as other less invasive options. A basic
understanding of the various surgical techniques is
therefore important. This permits accurate and compre-
hensive reporting of pre and post operative images.The Bentall composite graft
The first published description of the original valved
graft conduit repair of the aorta was in 1968 by Bentall
(Figure 7) [60]. The technique was developed to allow
treatment of those patients with aortic root aneurysm or
dissection in whom the proximal aortic rim was insuffi-
cient to allow the suturing of a tubular graft and preser-
vation of the native coronary ostial anatomy. Instead, the
tubular graft was sutured directly onto the ring of a Starr
valve and this was inserted en bloc. Holes were then cut
in the aortic prosthesis to allow reinsertion of the coro-
nary arteries.
Originally the graft material was unsealed and had to
be pre-clotted outside the patient. This changed as pre-
sealed material became available; then factory-made
composite grafts and finally a revision of the coronary
re-implantation technique with use of an aortic button
[61]. As a consequence of increased operator experience
and technical revisions the 30 day mortality from this
operation fell to approximately 1.5% for elective casesFigure 7 Bentall procedure.[54,62]. However, rates for emergency repair remain sig-
nificantly higher. 75% 10 year survival is reported, yet con-
cerns persist with regard to long-term thromboembolic
risks and the need for ongoing anticoagulation in such a
young patient cohort who remain at life-long risk of fur-
ther dissection. Some have therefore tried to use total root
replacement surgery using tissue valves [63].
Valve-sparing procedures
The aortic valve is a complex structure which cannot be
matched by any prosthesis. The 3 cusps are more than
passive sails, they interact with the root and LVOT. Aor-
tic valve cusps are thin-walled pocket-like structures, yet
strong and non-thrombogenic . The aortic root moves
during cardiac cycle in a manner preceding and aiding
opening and closing of AV [64-67]. Against this back-
ground valve-sparing root surgery was developed.
First Yacoub, then David proposed valve-sparing sur-
gery [68,69] using variations of root replacement by an
artificial graft with preservation of the patient’s native
aortic valve.
In both, the sinuses of valsalva are resected first and a
3-4 mm rim of tissue to both sides of all commissures
and along the attachment line of the cusps and coronary
ostiae is left. The aortic root is replaced by a graft. The
valve is then reimplanted into the vascular graft using a
form of David technique or: can be remodelled into it as
per the Yacoub technique (Figure 8).
In the Yacoub remodelling technique the graft first
needs to be incised at its base so that the 3 commissures
of the valve can be sewn into the 3 ‘tongues’ of the graft.
Hence pseudo-sinuses are created within the vascular
graft. The sinuses within the aortic root are considered
important for aortic valve function and coronary perfu-
sion. Finally the coronary ostiae have to be reimplanted
into the graft.
In the original David re-implantation technique the vas-
cular graft is placed over the native aortic valve and se-
cured below the aortic valve attachment. Then the aortic
valve and commissures are secured within the graft. As a
result the valve sits within the tubular graft without the
formation of pseudosinuses. Again the coronary ostiae
have to be reimplanted.
The results of the original David procedure are generally
considered to be better than with the Yacoub procedure
in MFS. This may be related to the restricted movement
and reduced distensibility caused by the original David
procedure. It is also hypothesised that the graft incisions
in the Yacoub procedure might limit the ability of the graft
to reduce further annular dilatation in MFS [70]. This re-
mains the case even with additional annuloplasty.
The David technique has been revised several times
and forms of version V are currently in use [71]. This re-
tains the implantation of the valve within the graft, but
Figure 8 The David and Yacoub valve-sparing techniques for aortic root replacement.
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ses. Interestingly, time-resolved 3D MR velocity mapp-
ing can demonstrate formation of coronary cusp vortices
post David repair, even in the absence of pseudosinus
formation [72].
Valve - sparing versus non valve-sparing surgery
A recent systematic review of the surgical management
of aortic disease in MFS compared the results of total
root replacement (TRR) versus valve-sparing aortic root
replacement (VSRR) [73]. The longer established TRR had
been performed in the majority with a mean follow-up of
8 years; for VSRR the figure was 4.7 years. VSRR was asso-
ciated with a fourfold increased rate of reintervention on
the aortic valve (1.3% per year vs 0.3%); with reintervention
most likely in those undergoing remodelling of the root
(Yacoub technique). On the other hand, TRR was associ-
ated with a significantly higher rate of thromboembolism
(0.7% per year versus 0.3% per year). There was no differ-
ence between the two techniques in the composite valve-
related event. However, durability data for VSRR are still
lacking and further registry data are awaited.
Both the American and European guidelines advocate the
use of valve-sparing operations with root replacement in
cases in which the aortic valve is anatomically normal and
in high-volume centres. Only if valve-sparing surgery is not
possible then root replacement with a valved graft conduit
is advocated. However, caution is expressed with regard to
long-term durability of residual aortic valve function and in
this context the American guidelines recommend a reim-
plantation technique rather than remodelling.External aortic root support
A further surgical technique has been pioneered and
evaluated by NICE in 2011 [74]. An individualised exter-
nal aortic root support (EARS) is used to reinforce the
ascending aorta while leaving the native aortic valve in-
tact and conserving the blood/endothelium interface
[61]. Robicsek suggested many years ago that wrapping
the aorta externally could prevent expansion. However
the results of this early operation have not been good
[75]. Furthermore, in the context of an already dilated
aorta, the compromise of a hand-tailored external sup-
port at a time when “off the shelf” composite valve con-
duits were becoming available was worrying and not
adopted in the main [54]. However, modern imaging and
engineering methods have allowed us to revisit that idea.
The recent development is born of the motivation, skill
and creativity of a biomedical engineer with MFS who
was the first individual to undergo this procedure just
over 7 years ago. The clinical results for the first twenty
patients were published in 2010 [76]. Each patient under-
went CMR study of the aorta (more recently Cardiac CT
has also been used) to provide digital information to pro-
duce a 3D reconstruction of the aorta from the aorto-
ventricular junction to beyond the brachiocephalic artery
using dedicated computer-aided design software. This was
transformed into a thermoplastic model formed exactly to
the physical model of the patient’s aorta. The latter was
then used as the frame upon which the bespoke external
aortic support was manufactured from a medical grade
polymer mesh (Figures 9 and 10). At surgery, without the
need for bypass, the aorta was dissected away from
Figure 9 Example of black blood aortic CMR imaging, some of the measurements and the model made by computer aided design.
Reproduced from the Journal Royal Society of Medicine 2010:103:370-375 [76].
Figure 10 The aortic model covered with the external aortic
root support made from a medical grade polymer mesh.
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support. The external support was secured without any
direct incision or suturing of aortic tissue. Whilst current
follow-up data is very hopeful for long-term outcomes,
should surgery be required on any part of the aorta in fu-
ture in these patients, the avoidance of anticoagulation will
be of benefit [77]. This approach has a number of potential
advantages over standard treatment for Marfan Syndrome:
1. External support may reduce mechanical stress on
the aortic wall, thus reducing repetitive mechanical
injury due to the pulse wave and retarding the
degenerative process.
2. The operation can be performed without the need
for cardiopulmonary bypass, myocardial ischaemia
or circulatory arrest.
3. It avoids replacing the aortic valve and therefore
life-long anticoagulation
NICE recognise that at the present time the outcome
data is based on a relatively small number of patients
and further data with regards to long term outcomes is
awaited. Hence this procedure is undertaken by special-
ist teams only with collection of audit and clinical data.Endovascular stent grafting
Endovascular stent grafting has been used in a few cases,
however, long-term data are lacking and there are concerns
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pressure of the stent over a long time. Such an approach
should only be considered if the risks of open repair are
prohibitive [57,78]. Aortic surgery has also been success-
fully combined with cardiac transplantation or left ven-
tricular assist device implantation in patients with MFS
[79,80].
Cardiac imaging
With the ever growing appreciation of the complex
manifestations of MFS, it has become apparent that pa-
tients need assessment of the entire aorta and careful
study of valves and biventricular function [81]. As the
number and quality of available imaging modalities has
increased, it should have become ever easier to provide
this imaging. However, a review of the literature reveals
a heterogeneity of approaches and intermodality vali-
dation based on techniques or views which may not be
routinely used. It is worth reviewing the current guide-
lines before reviewing each imaging modality individu-
ally, with an emphasis on cardiovascular MR (CMR).
Imaging guidelines
The European guidelines recommend using 2 modalities
in each patient and make recommendations for both
diagnostic and follow-up imaging [57] (Table 5).
American guidelines also recommend a TTE is per-
formed at diagnosis to establish aortic dimensions, ven-
tricular and valvular function, however, it should be
repeated at 6 months to establish the rate of change of
aortic parameters. If there is no significant change then
annual TTE will suffice. If however there is significant aor-
tic expansion or the initial aortic diameter is >4.5 cm, then
more frequent imaging is advised. The guidelines recognise
that most patients with MFS also undergo X-ray computedTable 5 European guidelines for imaging in MFS
Diagnostic Follow-up
TTE of aortic root: measure at annulus,
sinuses of Valsalva, sinotubular
junction and distal ascending aorta.
TTE on an annual basis if stable
TTE of left ventricular and
valvular function.
Either CMR or CT of entire aorta * CMR or CT of entire aorta: every
5 yr if normal aortic dimensions
beyond root; at least annually if
aneurysm formation beyond root.
Avoid coronary angiography due to increased dissection risk
CT coronary angiography pre-op
to assess for coronary disease
where possible
TOE- only in assessment of
suspected aortic dissection
*CMR assessment of aortic wall biophysical properties may be possible – see
CMR section below.tomography (CT) or CMR but they do not give any specific
guidance in this respect. They note that measurements
made on these modalities are 2-4 mm greater than those
on TTE, but it is on these external diameter measurements
that surgical intervention is usually planned. TOE is again
reserved for the setting of dissection.
Following surgical repair of the aortic root or ascending
aorta, lifetime imaging of the entire aorta is recommended,
in line with the European position.
Specific consideration is given to women with MFS dur-
ing pregnancy and monthly or bimonthly echo is recom-
mended in those with aortic root or ascending aortic
dilatation. If the more distal aorta is affected then CMR
without gadolinium may be used for monitoring during
pregnancy.
The American guidelines address more than just the
choice and timing of modality. They stress the impor-
tance of the comprehensive and reproducible nature of
reporting of aortic disease which is key in MFS. An
aneurysm is defined as: ‘a permanent localised dilatation
of an artery, having at least a 50% increase compared
with the expected normal diameter of the artery in ques-
tion.’ The term ‘ectasia’ refers to lesser degrees of arterial
dilatation.
Analysis of aortic images should be undertaken at a
workstation which permits rotation of the acquired images
to review each segment of the aorta and its branches. Re-
ports should contain essential elements and measure-
ments of aortic diameter should be taken at reproducible
landmarks, perpendicular to the longitudinal or flow axis
of the vessel (Figure 11). Diameter measurements from
axial images are highlighted as being inherently incorrect
unless properly aligned.
Recognition of the detailed analysis required to pro-
duce robust reports is welcomed by imagers. This is in
keeping with SCMR guidance on analysis of thoracic mag-
netic resonance angiography and the multiple sequences
which may be required for a comprehensive study of the
aorta [82]. SCMR also recognises the need for timely
reporting which will be influenced by clinical urgency, but
ideally within 24 hours of a routine scan a finalised report
should be available. As a minimum SCMR recommends
measurement at the aortic annulus; sinuses of Valsalva,
sinotubular junction and ascending and descending di-
ameters at the level of the pulmonary artery. It is also
recommended to report, when present: sinotubular efface-
ment, tortuousity, aortic aneurysm and aortic dissection
[83]. An aneurysm should be described in terms of size,
morphology, location, mural thrombus, local effects on
surrounding structures, post contrast appearance (if con-
trast given) and any pericardial, pleural, mediastinal or
periaortic fluid. A similar level of detail is required for de-
scription of a dissection (either Stanford or De Bakey clas-









Figure 11 CMR aorta demonstrating standard imaging landmarks for the thoracoabdominal aorta advocated by guidelines. 1: Aortic
sinuses of Valsalva 2: Sinotubular junction 3: Mid ascending aorta 4: Proximal aortic arch (at origin of inominate artery) 5: Mid aortic arch
(between left common carotid and subclavian arteries) 6: Proximal descending thoracic aorta (approx 2 cm distal to left subclavian artery) 7: Mid
descending aorta 8: Aorta at diaphragm (2 cm above origin of coeliac axis) 9: Abdominal aorta at origin of coeliac axis.
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visible.
The American guidelines for CT and CMR recom-
mend that the external aortic diameter should be mea-
sured and at the root the widest diameter, usually at
mid-sinus level, should be taken. The latter also applies
in echo but here the internal diameter should be mea-
sured [33]. However the rationale for this is that lumen
size may not accurately reflect external diameter in the
setting of mural thrombus, intramural haemtoma, throm-
bosed false aneurysm and aortic inflammation. Yet in the
setting of normal aortic wall thickness, measuring exter-
nal diameter will add a few millimeters (~3-4 mm) to the
size of the aorta compared with the internal diameter
measurements which may have impact on the timing of
surgery/intervention. Furthermore, this will be at disparity
with the echo measurement. In addition, most of the data
and cutoff values used for surgical intervention are based
on echo internal diameter measurements. Indeed, the
guidelines state that Marfan aorta of more than 5 cm is at
risk but avoids saying whether that’s internal or an exter-
nal diameter.
In our centres we are still using internal aortic diameter
measurements but are vigilant for any abnormal aortic
wall pathology (e.g. intramural haematoma, dissection, ul-
ceration, aortitis, etc.) and describe these lesions with mea-
surements separately in the CMR/CT reports to address
the guidelines’ concerns. We also have lots of patients whohave been followed up for years using internal diameter
measurements and as a group (imagers and surgeons),
we felt that it is important to have continuity in these
measurements.
In essence, to minimize errors, it is important that when
following up patients for changes in aortic dimensions
that measurements should be done at a reproducible ana-
tomical plane perpendicular to the axis of flow and any
abnormality of the aortic wall described and measured.
When possible measurements should be indexed to body
surface area.
Radiation exposure should be minimised wherever
possible. Invasive angiography is no longer considered as
a first-line investigation for aortic diseases and is rarely
used in this setting.
Imaging modalities
Echocardiography
The portability, safety and cost-effectiveness of TTE
have facilitated its fundamental role in both the diagno-
sis and monitoring of the aortic root in those with MFS.
M-mode recordings were used to establish the effect of
propranolol on the aortic root [19]. Recent studies have
also used M-mode interchangeably with 2D-images to
assess aortic root size [59]. Subsequent work has been
undertaken which validates ‘inner edge to inner edge’
measurements of the proximal aorta against TOE [84] and
TTE forms an integral part of most imaging guidelines in
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ity in the approach to TTE root measurement [85].
Yet the strength of TTE is that it may also assess
valvular and biventricular function in both adults and
children. As our understanding of MFS has grown, the
assessment and monitoring of biventricular function per
se should be part of our assessment, with tissue doppler
imaging incorporated into any protocol used, although
this has yet to feature explicitly in guidelines [86]. Chest
wall deformities preclude adequate imaging in only the
minority of patients with MFS.
TOE is used mainly in the setting of suspected acute
aortic root dissection in MFS. In experienced hands it
has a sensitivity and specificity comparable to CT and
CMR [87]. The echocardiographic diagnosis of dissec-
tion requires demonstration of a dissection flap separat-
ing true and false lumens. There may be more than one
intimal tear present and colour Doppler may be used to
show differential flow on either side of a flap. The true
lumen usually expands during systole and collapses dur-
ing diastole with forward flow during systole. A false
lumen shows the reverse expansion pattern, accompa-
nied by reversed, delayed or absent flow. Spontaneous
contrast may be present. Assessment of aortic valve com-
petency, presence of pericardial effusion and involvement
of the coronary ostia may help guide surgical intervention.
Increasingly intra-operative TOE is being used for assess-
ment and monitoring. However, as a semi-invasive pro-
cedure which has the potential to raise a patient’s blood
pressure, it is not used for routine aortic surveillance
(Figure 12).
X-ray computed tomography (CT)
CT is one of the longest serving imaging modalities in
the assessment of aortic disease. It is a rapid test which
can be used in either the acute or chronic disease settingaortic 
valve
Figure 12 a) Dilated aortic root on transoesophageal echo with evideto evaluate the entire aorta and periaortic structures. It
can distinguish between acute aortic syndromes and elu-
cidate branch vessel involvement. With the advent of
ECG-gating, the risks of motion-artefact mimicking dis-
section have been greatly reduced. International Registry
data have previously shown CT to be the first-line inves-
tigation in acute dissection in 61% cases [88]. Sensitiv-
ities of up to 100% and specificities of 92-100% for
helical CT have been reported in this setting [87]. A non-
contrast study to look for intramural haematoma, followed
by a contrast study to identify a dissection flap and the
contrast extravasation of rupture is recommended [33].
The vascular tree from neck to pelvis can be rapidly im-
aged to provide valuable information to the referring team
and it is possible to obtain a CT coronary angiogram and
aortogram in one ECG-gated CT acquisition. CT features
which discriminate between the true and false lumen have
been described [89]. Axial measurements tend to over-
estimate the thoracic aortic diameter and measurements
planned from double-oblique images are preferred [90].
Recommendations on technical parameters for acquisition
and reconstruction are available [33].
Where used pre-operatively, cardiac CT offers the ability
to perform a complete evaluation of the thorax. In patients
with MFS this has the advantage of assessing the chest wall
and surgical access with particular reference to coronary
artery position, in those with chest wall deformities [91].
With the expansion in cardiac CT angiography, at-
tempts have been made to evaluate its performance in
valvular disease. A recent retrospective study comparing
CT with TTE calculated a 96% sensitivity and 93% sensi-
tivity for the diagnosis of mitral valve prolapse. However,
it should be noted that this required retrospective gating
to acquire the dataset and hence radiation exposure
ranged from 7-11 mSv between patients. However, when
retrospective gating has been required for other reasons,dissection  
flap
nce of dissection flap b) Transaxial view of aortic dissection.
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but also for an assessment of aortic valvular and left ven-
tricular function. Currently there are limitations in the
ability of CT to grade valvular dysfunction [92]. However
on mid-systolic images the tethered appearance of the aor-
tic valve resulting from sinus of Valsalva dilatation and
a triangular coaptation defect may be present in end-
diastole if aortic regurgitation is present [93].
The ability of CT to demonstrate and assess vascula-
ture is not in doubt and, in the acute setting it can allow
rapid diagnostic imaging assessment of an unwell pa-
tient. However, it is a technique involving the use of
ionising radiation. Therefore it is not ideally suited for
long term follow up, particularly in a young patient co-
hort whose lifetime accumulated dose could be consid-
erable. ECG-gated low-voltage techniques significantly
reduce ionising radiation exposure and minimise poten-
tial long-term harm [94].Aortography/angiography
Aortography was first used in the 1960s as a method for
assessing aortic dissection. However it is invasive, requires
the use of iodinated contrast and radiation. Whilst in the
setting of primary PCI it is still possible to find oneself diag-
nosing acute aortic dissection by this method, it is other-
wise rarely used and is not advocated in the setting of MFS.Cardiovascular magnetic resonance (CMR)
Advantages and limitations
CMR is not limited by acoustic windows and is free from
ionising radiation. The entire aorta can be imaged and
complications including aneurysm formation, dissection,
and previous surgery are well visualised. This makes it
ideal for long-term follow up of patients.
Anatomical information can be gained, including origin
and exit of intimal tears. CMR has equivalent sensitivity
and specificity to CT for diagnosis of suspected thoracic
aortic dissection, but is more accurate when the pre-test
probability of dissection is high [87]. It has been validated
against echocardiography for aortic root measurement
and is well recognised as being superior at demonstrating
the asymmetrical root dilatation which is often seen in
MFS [95].
CMR allows assessment of both global and regional
biventricular function and allows visualisation of the conse-
quences of valvular dysfunction. Blood flow can be assessed
in both normal and abnormal vessels. Reconstructions in 3
dimensions are a powerful tool for demonstrating anatomy
to colleagues and patients alike. Utilising various sequences
this technique is unsurpassed at characterising vascular and
myocardial tissue.
The requirement for breath-holding limits the use of
CMR in the unstable patient; however, availability andexpertise are increasingly enabling studies to be tailored
to the individual patient.
Proposed CMR protocol
We offer the following CMR protocol for imaging a pa-
tient with MFS in the pre-operative setting, (Figure 13).
Protocol note: aortic distensibility assessment
High-resolution cine imaging in a plane perpendicular to
the ascending and/or descending aorta allows measurement
of aortic cross-sectional area during systole and diastole.
Measurement of regional aortic distensibility by CMR is
calculated from the change in volume of an aortic segment
and from aortic pulse pressure estimated by a sphygmo-
manometer at the level of the brachial artery. The lumen of
the aorta is outlined manually on the computer screen to
measure the change in aortic area (ΔA) between diastole
and systole. Aortic distensibility can be derived from the
change in volume (ΔV = ΔA × slice thickness) of the aortic
segment divided by the aortic pulse pressure (ΔP) measured
by a sphygmomanometer [96]. Automatic measurement of
aortic cross-sectional area is also possible [97].
Aortic distensibility ¼ Amax Aminð Þ=Amin
pulse pressure;
Amax ¼ maximal aortic area mm2;
Amin ¼ minimum aortic area mm2;
Pulse pressure ¼ systolic diastolic blood pressure
mmHgð Þ:
The accuracy of the indirect measurement of the pres-
sure change needed to compute distensibility is limited as
it ignores the changes in the pressure wave as it propa-
gates through the arterial tree (a process known as ampli-
fication). Further, it is important to obtain this pressure
data on patients ideally lying in the CMR scanner using
CMR compatible apparatus. Despite the limitations of the
pressure measurement, there is a good correlation be-
tween measurement of local aortic compliance and mea-
surement of global compliance from the speed of the
propagation of the flow wave within the vessel [98].
Flow wave velocity is defined as the speed with which
a flow wave propagates along a vessel and is regarded as
the purest measure of arterial stiffness. It is the quotient
of distance travelled divided by the time taken for the
flow wave to move between the two points and repre-
sents an average for that length of vessel. The approach
is dependent on assessment of path-length travelled and
accurate measurement of pulse arrival time. The latter
requires recognition of equivalent features or points on
leading edges of the proximal and distal flow waveforms,
a process made complicated by alterations that occur in
flow wave morphology and magnitude as it progresses
down the vessel. Unlike non-invasive measurements rely-
ing on linear, transcutaneous measurements, CMR makes
Figure 13 CMR protocol. Key to protocol abbreviations: trans = transaxial; cor = coronal; sag = sagittal; MV = mitral valve; AV = aortic valve;
MRA = magnetic resonance angiography; TSE = turbo spin echo. Typical Imaging Parameters and points to note: Aortic SSFP- FoV Read
320 mm, slice thickness 7 mm, flip angle 800, voxel size 1.7 × 1.7 × 7.0 mm. TSE – 5–10 parallel images planned from a transverse stack along long axis
of aorta. Image position can be copied from Half-Fourier Single Shot TSE or SSFP stacks. For T2 weighted TSE: FoV Read 340 mm, slice thickness 6.0 mm,
TR 700 ms, TE 81.0 ms. For T1 weighted TSE: FoV Read 340 mm, slice thickness 6.0 mm, TR 750 ms, TE 31.0 ms. CE-MRA- Give 0.1-0.2 mmol/kg
gadolinium. Images should be reconstructed in MPR and analysed in thin MIP. 3D Navigated SSFP MRA- FoV Read 320 mm, slice thickness 1.5 mm, flip
angle 900, voxel size 1.0 × 1.0 × 1.5 mm.
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curately measure the path-length travelled.
Follow-up studies
What is most important in assessment of the aorta is ac-
curacy and reproducibility. These patients are attending
for lifelong follow-up and variation in measurement
techniques could have disastrous consequences.In CMR there is a surprising lack of standardisation of
methodologies. In part this stems from the flexibility of
the technique, with multiple types of sequences offering
the ability to derive information about the aorta. For ex-
ample, ECG-gated end-diastolic black-blood images using
spin echo can be used to assess anatomy and morphology;
SSFP-based cine images can be used to do the same.
Contrast-enhanced MRA may be used but this is usually
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artefact, particularly in the aortic root.
With such a wide choice available one should be aware of
the advantages, limitations and differences between the se-
quences and the measuring planes. In recent years a body
of work has been undertaken to investigate this further.
Measurements of the aortic root can reliably be obtained
from SSFP-based cine images. Sinus of valsalva planes can
be planned from oblique sagittal and oblique coronal
LVOT planes. Sinus-sinus and sinus-commissure measure-
ments taken at end-diastole are most comparable with echo
and reference values are available (Figure 14) [99], It is im-
portant to quote the maximum trans-sinuses measurement
which is usually the sinus-sinus measurement in the report.
It is well recognised that aortic size can be significantly
overestimated by axial measurements when compared with
orthogonal measurements when the aorta is not straight
and the axial plane is not perpendicular to the true axis of
the aorta. This could affect management decisions in up to
13% patients and has led some investigators to advocate
the use of contrast-enhanced magnetic resonance angiog-
raphy (CE-MRA) in patients, where possible with ECG-
gating to minimise aortic root motion-induced artefacts.
However, this appears to be rarely done in clinical practice
[100]. When CE-MRA is used, careful reconstruction of
images is required. Unfortunately without ECG-gating it is
the root measurements which are the least reliable, but
normal values have been generated for various patient
groups [101].A. B
DC.
Figure 14 SSFP-based imaging. A, An oblique sagittal LVOT cine at end
measurements (white arrow, black line, and black arrow, respectively). B, An
measurement. C, A systolic sinus plane image, showing 3 cusp-commissure
lines, respectively) with the cross-sectional area outlined in white. D, An en
cusp-cusp lines of measurement. Reproduced with permission [99].In response to concerns about regularly performing
CE-MRA with gadolinium in patients, a non contrast-
enhanced MRA using 3D-navigated SSFP has been trialled
[102]. Although it has had some success, it is susceptible
to arrhythmia and adds approximately 10 minutes to the
scan time. Comparison of 3D-navigated SSFP with CE-
MRA, 2D T2 black blood (BB) and 2D SSFP-based cines
has been reported. [103] 3D-navigated SSFP and CE-MRA
provide the largest aortic measurements and T2 BB the
smallest. T2 BB has the best inter-observer variability but
all sequences have an inter-observer variability of >0.9.
Vessel wall analysis is optimal on T2 BB images. 3D-
navigated SSFP measurements correlated best with the
gold standard of ECG-gated CT, but the images are less
sensitive for demonstrating dissection flaps when com-
pared with CE-MRA.
It is reasonable to derive from these studies that sev-
eral sequences should be used to assess the aorta in
patients with MFS. Our ‘basic’ T2 BB and 2D SSFP se-
quences can produce beautiful images from which ex-
tremely detailed and reliable measurements can be made
[104]. However CE-MRA can be of particular use when
assessing a tortuous aorta and navigated 3D-SSFP may
be used in those in whom renal impairment is an issue.Clinical application
The following sections contain examples of black blood,
SSFP and CE-MRA images used in clinical context..
. 
diastole showing the levels of annulus, sinus, and sinotubular junction
oblique coronal LVOT cine showing the equivalent levels of
and 3 cusp-cusp lines of measurement (continuous and dashed black
d diastolic sinus plane image, showing the cusp-commissure and
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A description of the classification of aortic dissection
and complications is given in the section on the aorta.
Figure 15 demonstrates aneurysmal involvement of the
subclavian arteries in a patient who has undergone previ-
ous surgery. Figure 16 demonstrates black blood imaging
of a type A dissection and Figure 17 demonstrates post-
operative SSFP imaging of a dissection which involved the
ascending aorta, but also the head and neck vessels with a
visible flap in the proximal descending aorta.
Valves
Whilst the primary purpose of CMR in MFS is usually
aortic assessment, it is also capable of providing useful in-
formation on valvular function. SSFP-based cine imaging
in an LVOT view can reliably detect mitral valve prolapse
[105]. The anatomical basis for regurgitation can then be
investigated by performing a mitral valve stack. This is a
contiguous stack of 5 mm slices aligned with MV inflow
and cutting through the major line of coaptation. It should
move from the superior to inferior commissure in the
LVOT view. In this way the scallops of both leaflets may
be demonstrated. Any regurgitation may be quantified:
Mitral regurgitant volume
¼ LV stroke volume aortic forward flow
ðml=cardiac cycle fromaortic flow analysis at
level of the STJÞ
Regurgitant fraction
¼ regurgitant volume=LV stroke volume 100%
The aortic valve should be assessed well by a standard
CMR protocol. The LVOT and coronal LVOT SSFP-Figure 15 CE-MRA Demonstrating Bilateral Subclavian Artery Aneurysm
examples highlighted by arrows.based cines will demonstrate AR as a signal void. The
‘en face’ AV view planned from the LVOT views will
demonstrate abnormal cusp morphology or defects in
coaptation. However cine images alone should never be
used to quantify any degree of regurgitation.
Through-plane velocity flow mapping at the STJ should
be performed to quantitatively assess AR.
Aortic regurgitant volume in ml/cardiac cycle is the
reverse flow from analysis of flow mapping.
Regurgitant fraction
¼ regurgitant volume=aortic forward flow in
systole 100%
This method will underestimate the degree of AR
since the slice is at the level of the ST-J and does not ac-
count for annular motion and coronary perfusion during
the cardiac cycle (see Figures 18,19 and 20).
Cardiomyopathy/Assessment of ventricular function
and volumes
CMR is the gold standard for biventricular assessment and
can detect the mild ‘DCM phenotype’ of MFS cardiomyop-
athy (see myocardial involvement in MFS). Several CMR
software packages allow rapid analysis of biventricular vol-
umes and function. If a more focused approach is required
clinically then LV analysis can be performed. If LVEF is
abnormal, in the absence of valvular dysfunction or other
aetiology, then RV analysis should be performed [53]. Not-
ably, ventricular impairment due to MFS is usually global,
hence any regional dysfunction warrants further clinical in-
vestigation and tissue characterisation eg with LGE to ex-
clude concomitant pathology, (see Figure 21).s in a Patient who has undergone Previous Aortic Root Surgery,
Figure 16 Black blood (spin echo) imaging before (coronal) and
after (sagittal) emergency VSARR for type A dissection. Note the
significant reduction in aortic root dimensions.
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After intervention or open surgery, the American guide-
lines advocate the use of CT to detect asymptomatic
leaks or pseudoaneurysms if metallic surgical devices are
likely to cause significant artefact. On a pre-discharge
CT, non-contrast images may be used to identify surgicalFigure 17 SSFP sagittal oblique image following emergency
repair of type A dissection- residual dissection in proximal arch
extending into right common carotid artery. Communication
between true and false lumens in proximal descending aorta is
evident. Dissection flap highlighted by arrow.materials which can be difficult to distinguish from leaks
on contrast-enhanced images. However use of retro-
spective gating means this comes with an increased dose
of radiation [91].
When artefact is not an issue, and usually it is not, then
CMR may be used. CMR has been used very successfully
to identify complications after prosthetic replacement
of the ascending aorta for over a decade [106]. A post–
operative study within the index admission is advised,
followed by repeats at 1,3,6 and 12 months and annually
thereafter [33]. The standard protocol suggested earlier
would allow comprehensive post-operative assessment.
Peri-prosthetic leaks and haemopericardium can be
demonstrated on all static images and the sources deter-
mined on subsequent SSFP and velocity encoded phase
imaging. Using SSFP-based cine imaging aortic measure-
ments may be made and any residual dissection flap
visualised. Slow flow and thrombus can be identified and
their presence confirmed on TSE sequences [107]. If ne-
cessary, through-plane flow mapping can be used to as-
sess true luminal flow. CMR has the added value of
easily quantifying post-operative biventricular function
unhindered by chest-wall anatomy. If renal function per-
mits, then LGE should be performed (see below).
It is essential to corroborate findings with the operative
notes and TOE and postoperative TTE. By doing so any
graft angles or tied-off cannulation sites should not be
mistaken for further dissection or pseudoaneurysm forma-
tion. In addition, proximal and distal graft anastomoses
and coronary reimplantation sites can be identified.
Following a VSARR, imaging serves a number of im-
portant roles:
1. Define post-operative anatomy including surgical
materials e.g. graft, Teflon strips, pledgets, Bioglue.
2. Identify haematoma or leak at proximal and distal
graft anastomoses and coronary reimplantation sites.
This may be localised or take the form of extensive
haemopericardium.
3. Assess valvular function and look for paravalvular leaks.
4. Assess ventricular function. Perioperative myocardial
infarction secondary to prolonged hypotension or
difficulties with coronary reimplantation has been
reported and should be readily defined on LGE.
5. Look for residual dissection and thrombus - a patent or
partially thrombosed false lumen at the time of primary
surgical repair is known to increase this risk [108].
6. Look for infection – either graft or sternum (See
Figures 22, 23, 24, 25 and 26)
Additional notes on assessment of the biophysical
properties of the aortic wall and the future
Without question CMR is an elegant technique for com-
bining anatomical and functional assessment. In MFS
Figure 18 Bileaflet prolapse of the mitral valve at end systole (see arrow) on 4-chamber and LVOT SSFP images.
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properties of the aortic wall [109].
The aorta is more than just a conduit for passive blood
flow. It is an elastic tube, the diameter of which varies in
response to haemodynamic forces, transforming the pul-
satile ventricular output into a continuous flow of blood
to the peripheries. This ‘distensibility’ depends in large
part on the elastic content, arrangement and maintenance
of the vessel wall which is altered in MFS.
CMR is well placed for the assessment of aortic disten-
sibility, the method is described and illustrated in thea b
d
Figure 19 T1 weighted spin echo image (a) and SSFP imaging in dias
type A dissection (large arrow) and functional severe eccentric AR (shCMR protocol section. This technique has been vali-
dated against echocardiographic assessments in several
studies [110,111]. However, CMR has superior anatom-
ical reproducibility in terms of anatomical landmarks
and hence is more valuable and reproducible in terms of
follow up. The process by which aortic contouring is
performed is still being refined [112].
Compliance is the reciprocal of the resistance to de-
formation and is defined as the change in volume per unit
change in pressure (microml/mm Hg). Regional aortic
compliance has been studied by CMR, using a formulac
e
tole (b-d) and systole (e) of classical aortic root dilatation with
ort arrow) before repair.
Figure 20 Diastolic (a-c) and systolic (d) frames from complete cine SSFP imaging showing appearance after successful valve- sparing surgery.
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http://www.jcmr-online.com/content/15/1/33similar to that for assessment of distensibility, but using
slice thickness to calculate the volume of blood in each
aortic segment studied [96].
At a systemic arterial level compliance has been assessed
echocardiographically in patients with MFS and used toFigure 21 Anterolateral infarction with transmural enhancement in a pa
left and top; lower image is equivalent 4-chamber image following administraassess response to pharmacotherapy [22,85]. In this context
compliance is not assessed by means of pressure changes,
but rather by the speed of propagation of the pulse wave
velocity (PWV), which is generally higher as distensibility
decreases. This speed of propagation is regarded as thetient with a previous aortic root repair. (SSFP images without contrast
tion of gadolinium. Arrow demonstrates transmural enhancement).
Figure 22 Normal appearance of a VSARR on SSFP-based imaging. The upper panels demonstrate the aortic valve in diastole and systole;
lower panels demonstrate aortic appearance.
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http://www.jcmr-online.com/content/15/1/33purest measure of arterial stiffness. In the aorta it is usually
calculated as the ratio between the distance separating 2
points of interest and the time taken for a pressure/velocity
wave to travel this distance. The feasibility of this measure-
ment by CMR was demonstrated over 15 years ago [98].
With its unlimited views, CMR is well placed to accurately
assess the length of aorta travelled by the PWV, even when
chest wall or aortic anatomy is distorted. Exploiting the
aortic anatomy it is possible to select an anatomic slice,Figure 23 Tortuous abdominal aorta, previous VSARR and thoracoabdo
proximal to brachiocephalic artery (straight arrow). Proximal descending archusually at the level of the pulmonary bifurcation, from
which a phase contrast/velocity encoded image can be ac-
quired, in a plane perpendicular to the aortic lumen. In this
one slice, phase velocity maps which can be used for quan-
tifying blood volume flowing through the imaging plane,
can be generated for 2 aortic levels [113] (See Figures 27
and 28).
Although multiple flow imaging techniques have been
tried in CMR, it is the phase velocity/velocity encodingminal graft. Root replacement anastomosed to upper ascending aorta
is anastomosed to thoracoabdominal gaft (curved arrow) on CE-MRA.
Figure 24 Haematoma outwith graft following a Bentall procedure on SSFP (coronal, sagittal and transaxial in upper panel) and black
blood imaging (lower panel).
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http://www.jcmr-online.com/content/15/1/33technique which is the most utilised. However, the optimal
method for estimation of transit time from the resultant
velocity curves remains under review [114]. Research is
currently focused on a revision of the traditional 2-slice
method to a two-directional in-plane velocity-encoded
CMR covering the entire aorta in 3 parallel oblique-sagittalFigure 25 Para-aortic haematoma (arrowed) – previous aortic root ho
left, sagittal TSE BB in upper right, SSFP imaging lower right in transaslices and, more recently, to a 4-slice breath-hold through-
plane velocity-encoded CMR [115,116]. This technique
may be particularly useful in predicting lack of luminal
growth in the ascending aorta [117].
Indeed for some time investigators have recognised
the importance of both aortic diameter and distensibilitymograft and re-do surgery (SSFP imaging in sagittal view on the
xial cut, also demonstrating right pleural effusion).
Figure 26 Subcutaneous infected collection visible externally and on CMR, courtesy of Dr Sonya Babu-Narayan.
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http://www.jcmr-online.com/content/15/1/33in predicting aortic events in those with MFS [118]. For
the aortic root and abdominal aorta it is the initial diam-
eter which is the major predictor of progressive dilatation
and dissection, although distensibility is also reduced; for
the thoracic descending aorta, local distensibility is an in-
dependent predictor. In one study a cut off of a distensi-
bility of 3.1 × 10-3 mmHg -1 was found to have sensitivity
of 100% and specificity of 56% for lack of progressiveAA
DA
Diastole
Figure 27 Upper panel shows an oblique sagittal image of the aorta
compliance are measured. The lower images represent the oblique trans
(AA ascending aorta; DA descending aorta).dilatation. An annual assessment of aortic distensibility as
well as diameters at 4 aortic levels has been proposed
[119]. In addition it is possible to assess changes in aortic
distensibility and PWV in response to beta-blockade in
patients with MFS, although such an approach has not be-
come routine clinical practice [120]. (It is worth noting
that in those with MFS, even though beta-blockade signifi-
cantly increases aortic root distensibility, it still remainsSystole
demonstrating sites where flow wave velocity and regional
verse plane in diastole (left) and systole (right), in a healthy individual.


































Figure 28 Demonstrates assessment of pulse wave velocity. Phase velocity acquisition across a vessel is undertaken at points 1 and 2 and
the distance between them is measured. Slice prescription for the proximal pulmonary arteries and the aorta are both demonstrated. The
descending and ascending aortic locations are obtained within a single slice. Transit time is defined by the difference in arrival time of the flow
wave at points 1 and 2 and divided by the distance to give pulse wave velocity. (MPA main pulmonary artery; LPA left pulmonary artery; RPA
right pulmonary artery). Reproduced with permission from Cardiovascular Magnetic Resonance, Second edition, Manning WJ and Pennell DJ.
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http://www.jcmr-online.com/content/15/1/33significantly less than in control subjects in this study.)
Other studies have demonstrated a heterogeneous re-
sponse to beta-blockade with regard to aortic elasticity
and, in these individuals, a combination of CMR assess-
ment of aortic biophysical properties and blood pressure
measurements may demonstrate that the aorta is already
‘under strain’, utilising not only elastin but also collagen to
support daily ‘load bearing’. These patients would be less
likely to benefit from beta-blockade [121].
Distensibility may even be used as a screening tool in
family members who do not appear to have the MFS
phenotype [122]. Similarly, parameters of aortic compliancecan be abnormal in young patients with MFS and normal
aortic dimensions [123]. Although in those with MFS, dis-
tensibility may be abnormal in most parts of the aorta
which are studied, it is possible that the values obtained in
some segments may overlap with the normal range. In
these situations, the assessment of the PWV will demon-
strate the abnormalities [109]. However, a comprehensive
assessment of distensibility at several aortic levels, including
the aortic root, is also likely to demonstrate abnormalities
in an individual with MFS and hence in a pragmatic clinical
study this is an appropriate and reproducible undertaking.
Of note, aging has a progressive negative effect on aortic
Dormand and Mohiaddin Journal of Cardiovascular Magnetic Resonance 2013, 15:33 Page 25 of 28
http://www.jcmr-online.com/content/15/1/33compliance. However, in MFS, the values obtained are sig-
nificantly different from healthy controls of an equivalent
age [124].
CMR is uniquely placed to assess morphology whilst
obtaining ecg-gated and spatially-encoded functional in-
formation. Therefore attention has now turned to more
detailed analysis of aortic flow in MFS by means of 4D
(time-resolved 3D) phase-contrast CMR [125-128]. How
this contributes to negative aortic modelling has yet to
be elucidated but is the subject of ongoing work [129].
In patients with MFS this technique has been used to
demonstrate aortic flow disturbance and to propose a
new flow-based classification of aortic disease in those
with MFS [130]. Previous alternatives to this approach
involved using CMR-derived parameters of the aortic
wall combined with computational fluid dynamics [131]
or CMR-derived aortic anatomical images reconstructed
and subjected to finite element analysis to determine wall
stress and hence risk of rupture [132]. The future may be
one of combining the assessment of an individual’s bio-
physical wall properties with an assessment of individual
flow patterns and shear stress to refine the timing of surgi-
cal intervention and the success of both pharmacological
and surgical intervention [72,125]. However this tech-
nique remains a research tool at present whilst its applica-
tions and limitations are fully elucidated [128,133].Conclusion
All guidelines recommend lifelong follow-up of the entire
aorta in patients with MFS. Yet data from the Euro Heart
Survey on adult congenital heart disease demonstrates
that within Europe we are falling well short of this [40].
Our goal is to best utilise the multimodality techniques at
our disposal to be accurate, reproducible and accessible to
those with MFS. CMR is an integral part of the imaging in
MFS, which dictates the timing and nature of intervention
and hence dictates our patients’ outcomes.Consent
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